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Background: Over the last twenty years diverse outcome measures have been used to 56 
evaluate the effectiveness of therapies for eosinophilic esophagitis (EoE). This systematic 57 
review aims to identify the readouts used in observational studies of topical corticosteroids, 58 
diet, and dilation in adult EoE patients. 59 
Methods: We searched MEDLINE, and Embase for prospective and retrospective studies 60 
(cohorts/case series, randomized open-label, case-control) evaluating the use of diets, dilation, 61 
and topical corticosteroids in adults with EoE. Two authors independently assessed the articles 62 
and extracted information about histologic, endoscopic, and patient-reported outcomes and 63 
tools used to assess treatment effects. 64 
Results: We included 69 studies that met inclusion criteria. EoE-associated endoscopic 65 
findings (assessed either as absence/presence or using Endoscopic Reference Score) were 66 
evaluated in 24/35, 11/17, and 9/17 studies of topical corticosteroids, diet, and dilation, 67 
respectively. Esophageal eosinophil density was recorded in 32/35, 17/17, and 11/17 studies 68 
of topical corticosteroids, diet, and dilation, respectively. Patient-reported outcomes were not 69 
uniformly used (only in 14, 8, and 3 studies of topical corticosteroids, diet, and dilation, 70 
respectively), and most tools were not validated for use in adults with EoE. 71 
Conclusions: Despite the lack of an agreed set of core outcomes that should be recorded and 72 
reported in studies in adult EoE patients, endoscopic appearance of EoE-associated findings 73 
and esophageal eosinophil density are commonly used to assess disease activity in 74 
observational studies. Standardization of outcomes and data supporting the use of outcomes 75 
are needed to facilitate interpretation of evidence, its synthesis, and comparisons of 76 
interventions in meta-analyses of therapeutic trials in adults with EoE. 77 
Word count: 255 78 




Eosinophilic esophagitis is characterized by presence of both symptoms related to esophageal 81 
dysfunction and esophageal eosinophilia.[1] In adults, esophageal inflammation driven by food 82 
antigens leads to the formation of fibrosis and strictures in a time dependent manner.[2,3] 83 
Dysphagia is a predominant symptom in adults with EoE. It is associated with various 84 
behavioral adaptations aimed at both avoiding and dealing with impaction episodes.[4] These 85 
adaptations include avoidance of certain foods, eating slowly, and consuming copious 86 
amounts of liquids during meal times. Therefore, capturing a full range of dysphagia 87 
experiences is a complex task. Nevertheless, in recent years, attempts have been made to 88 
assess frequency of dysphagia, albeit described using different patient language, as a patient-89 
reported outcome (PRO) in clinical trials and observational studies.[4,5] Of various 90 
inflammation- and fibrosis-associated histologic parameters, esophageal eosinophilia is most 91 
frequently assessed in clinical practice and observational studies. Evaluating the full spectrum 92 
of EoE-associated histologic findings outside of clinical trials remains a challenge.[6] Although 93 
not pathognomonic of this condition, EoE-associated endoscopic findings are often assessed 94 
as endpoints in various studies or used to aid clinical decision-making.[7] Measuring 95 
intraluminal distensibility using Endoluminal Functional Lumen Imaging Probe, genetic 96 
profiling, assessment of various biomarkers, and immunological dissection, such as measuring 97 
of allergen specific immunoglobulin levels, T cell profiling, barrier assessment, have also been 98 
carried out over the years; however, many of these parameters are assessed as a part of the 99 
exploratory investigations.[8,9,10,11,12,13,14,15,16] 100 
     EoE-associated endoscopic findings and esophageal eosinophilia represent the most 101 
common outcomes for the purposes of monitoring treatment efficacy/effectiveness in adults 102 
with EoE. Nevertheless, standardizing outcome assessment, whether in the context of 103 
randomized controlled trials (RCTs) or observational studies, remains a challenge. For 104 
example, Ma et al. have recently demonstrated that certain heterogeneity in use of clinical, 105 
endoscopic, and histologic outcome measures in RCTs in adults with EoE can be observed, 106 
and concluded that this may pose challenges for drug development.[17] Further refinement of 107 
 
 
tools used to assess outcomes in adults with EoE, use of data- and patient-driven approaches 108 
to define the response and remission for these tools, and development of the core outcome 109 
set (COS) to be reported in all clinical trials and observational studies are important steps 110 
towards improving and standardizing outcome assessment in this condition. Although uptake 111 
of COS may take a few years, adapting COS will pave the way for improved quality of evidence 112 
synthesis and will facilitate RCT design. In adults with EoE, assessment of symptoms using 113 
electronic daily diaries, histologic findings using eosinophilic esophagitis histology scoring 114 
system (EoE HSS), and other state-of-the-art outcomes, such as esophageal distensibility, is 115 
mostly carried out in the context of industry-sponsored registration trials. [18,19,20] Whether 116 
these same outcomes should be recommended for use in observational studies as part of COS 117 
remains to be determined. A substantial proportion of EoE research on response to various 118 
therapies during the past two decades has been reported in observational studies and non-119 
controlled trials. In this systematic review, we evaluated outcomes used in the observational 120 
studies of swallowed topical corticosteroids, diets, and dilation to inform outcome selection for 121 
the COS exercise in adults with EoE. 122 




Search strategy 125 
A systematic literature search was conducted in MEDLINE (Ovid, inception to January 1st, 126 
2021) and Embase for observational studies without language restriction. Citations and 127 
abstracts were screened for potentially eligible studies, and complete manuscripts were 128 
retrieved for full-text review. The search strategy is outlined in Supplementary File 1. Data from 129 
studies that met inclusion criteria were independently extracted by two investigators (ES, CS); 130 
discrepancies were resolved by consensus or in cases of discrepancy, review with a third 131 
author (AMS). The study was conducted in accordance with the PRISMA guidelines. 132 
Study Selection 133 
Included studies were prospective or retrospective case series, case-control, cohort, or quasi-134 
experimental studies of EoE adult patients (>18 years of age) that underwent treatment with 135 
one of the following therapies: corticosteroid, diet or dilation. Although trials are not the focus 136 
of this overview, we nevertheless also considered randomized open-label trials for 137 
completeness. Placebo-controlled clinical trials of children and adults, studies that included 138 
children and adolescents, and studies evaluating the use of therapies other than a 139 
corticosteroid, diet or dilation were excluded as these were the focus of previous systematic 140 
reviews.[17,21] 141 
Data extraction 142 
The following covariates were extracted: 1) study-related variables (study design, type of 143 
intervention, publication year, country/region of origin, calendar period, single- or multi-144 
centered, total participants, inclusion and exclusion criteria, number of treatment arms, 145 
duration of follow-up); 2) patient-related variables (demographic characteristics, presence of 146 
associated atopic conditions, age at diagnosis or enrollment, gender); and 3) outcome-related 147 
variables (description of quality of life, symptom-based, endoscopic, and histological 148 
outcomes; esophageal eosinophil count before and after treatment; definitions of response and 149 
remission if applicable; and use of measurement tools, scores, or validated instruments). 150 
Furthermore, we extracted information on whether blood markers were assessed or other 151 
 
 
experimental techniques were performed. Given that the focus of this review was on outcomes 152 
assessed in different studies (as opposed to the meta-analysis of changes in various outcomes 153 
in response to therapies), we did not exclude any studies with overlapping patient population. 154 
Data Synthesis and Analysis 155 
Standard descriptive statistics were used to summarize study characteristics. A list of 156 
outcomes and definitions produced by a qualitative review were summarized into the following 157 
categories: histologic outcomes, baseline and end-of-treatment esophageal eosinophil counts, 158 
endoscopic outcomes, quality of life and symptom-based outcomes, biomarkers/results of 159 
immunological dissection.  160 
     This systematic review conforms to the Preferred Reporting Items for Systematic Reviews 161 
and Meta-Analyses (PRISMA) recommendations. 162 




The flow diagram of the studies that were identified, screened, and included for purposes of 165 
this review is shown in Supplementary Figure 1. Of the 69 studies extracted for the purposes 166 
of this review, 58 studies were case series/cohorts, four were randomized open-label, and 167 
seven were case-control studies. A total of 35 studies examined the use of corticosteroids 168 
(swallowed topical fluticasone or budesonide or oral prednisolone), 17 studies examined the 169 
dietary therapy, and 17 studies examined the use of dilation in adults with EoE. The baseline 170 
study characteristics are shown in Table 1. 171 
Outcome reporting in studies of corticosteroid therapy 172 
Outcomes assessed in the studies of corticosteroid therapy are summarized in Tables 2 and 173 
5. Esophageal eosinophil density is the most frequently reported outcome assessed in studies 174 
of corticosteroid therapies. On its own, it has been reported in 20 studies. In another 12 studies, 175 
other histologic parameters, including presence of eosinophil abscesses, basal zone 176 
hyperplasia, spongiosis, mast cells, basophils, subepithelial fibrosis, were assessed. 177 
Definitions of response/remission included < 15 eosinophils per hpf (n=10), < 7 or ≤ 7 178 
eosinophils per hpf (n=2), and < 5 or ≤ 5 eosinophils per hpf (n=3).  179 
     At least four EoE-associated endoscopic features, including exudates, rings, edema, 180 
furrows, and strictures, were assessed in 23 studies of corticosteroids therapies. Of the 23 181 
studies, seven studies (published in 2014 or later) reported endoscopic outcomes based on 182 
the EoE Endoscopic Reference Score (EREFS) developed by Hirano et al.7 Of those, scoring 183 
algorithm/grading was reported in 5 studies. 184 
     EoE-specific symptoms were assessed in 31 studies. Dysphagia, either as 185 
absence/presence, frequency or severity, was the most commonly assessed EoE-associated 186 
symptom (assessed in 22 studies). In 14 studies, PRO tools were used. Other than the Mayo 187 
Dysphagia Questionnaire and Watson Dysphagia Scale, the remaining tools and the 188 
complementary scoring systems have not been previously validated. 189 
  190 
 
 
Outcome reporting in studies of dietary therapy 191 
Outcomes assessed in the studies of diet therapy are summarized in Tables 3 and 5. 192 
Esophageal density was assessed in all studies of dietary therapy, and additional histologic 193 
parameters (eosinophil abscesses, basal zone hyperplasia, spongiosis, mast cells) in six 194 
studies. Definitions of remission included < 15 eosinophils per hpf (n=8), ≤ 10 eosinophils per 195 
hpf (n=2), and < 5 or ≤ 5 eosinophils per hpf (n=4). In four studies, multiple remission definitions 196 
were used. At least four EoE-associated endoscopic features, including exudates, rings, 197 
edema, furrows, and strictures, were assessed in 11 studies, of which six used EREFS. Of the 198 
six studies using EREFS, the scoring algorithm was reported in 4 studies. Various 199 
characteristics of dysphagia (frequency, severity, duration) or else presence of dysphagia were 200 
assessed in 13 studies using primarily non-validated instruments; in eight studies, patients 201 
reported their symptom severity. General patient-reported quality of life was assessed using 202 
The Short Form-36 in three studies. 203 
Outcome reporting in studies of dilation 204 
Outcomes assessed in the studies of dilation are summarized in Tables 4 and 6. Esophageal 205 
eosinophil density at the time of dilation was assessed in 11 studies of dilation. Presence of at 206 
least four EoE-associated endoscopic features was assessed in 7/17 studies of dilation, and 207 
EREFS was assessed in 2/17 studies. Only three studies examined baseline dysphagia 208 
characteristics and the improvement in these characteristics following the dilation using non-209 
validated patient-reported outcomes measures. 210 




In this systematic review, we assessed outcomes used in observational studies in adults with 213 
EoE. We found that there was a considerable heterogeneity in outcome assessment in 214 
observational studies of adults with EoE, and our results are congruent with those obtained in 215 
systematic reviews of the outcomes used in pediatric and adult trials.[17,21] 216 
     We found that esophageal eosinophil count is the most reported outcome in studies 217 
evaluating the use of various EoE-specific treatments, but there was a lack of agreement on 218 
remission definitions and most remission definitions do not conform to the cutoff of ≤ 6 219 
eosinophils per hpf recently proposed by United States Food and Drug Administration (US 220 
FDA).[22] The remission definitions reported in observational studies are mostly comparable 221 
with those used in trials of adults.17 For example, the histologic cut-off of < 5 eosinophils per 222 
hpf has been used in both trials and observational studies; however, a more stringent definition 223 
of ≤ 1 eosinophil per hpf has been used in trials only. All these definitions are empirically 224 
chosen and likely do not define clinically relevant populations, but there are emerging data to 225 
support certain response thresholds.[23,24,25] In addition, adapting any one of them will not 226 
eliminate variability stemming from the differences in the cross-sectional hpf areas of various 227 
microscope manufacturer and normalizing density to eosinophils per mm2 should still be 228 
encouraged.26  EoEHSS proposed by Collins et al assesses grade (severity) and stage 229 
(extent) of eight histologic features including esophageal eosinophil density.6 Although this 230 
scoring system has been used in a number of clinical trials in adults and have shown to be 231 
valid, there is limited evidence that assessment of EoEHSS /additional features histologic 232 
features of EoE outperforms simple esophageal eosinophil count in pediatric and adult 233 
populations; therefore, these data are urgently needed.[6,18,19,20,27,28,29] Although not 234 
assessed using EoEHSS, the presence of basal zone hyperplasia, frequently encountered in 235 
patients with EoE, was associated with presence of symptoms and endoscopic findings in the 236 
absence of esophageal eosinophilia and hence might be suggestive of ongoing disease activity 237 
despite the lack of eosinophilia.[29] There are methodological challenges of addressing 238 
multicollinearity arising from associations between various histologic alterations, and 239 
 
 
elucidating the importance of assessing EoEHSS alterations other than esophageal eosinophil 240 
density and basal zone hyperplasia might further be hampered by the low prevalence of some 241 
of these findings in EoE patients and inability to consistently sample the lamina propria with 242 
mucosal biopsies. In summary, seeking community-wide consensus on the uniform 243 
esophageal eosinophilia remission definition and generating data supporting the assessment 244 
of additional histologic features other than esophageal eosinophil density are of particular 245 
priority for purposes of outcome reporting in observational studies and trials. 246 
     The EREFS grading and classification system by Hirano et al has been used in most recent 247 
clinical trials of anti-inflammatory therapies for purposes of regulatory approval, and its uptake 248 
for use in observational studies has been relatively swift.[7,18,19,20,24,30] Most studies report 249 
esophageal EoE-associated endoscopic findings in proximal and distal esophagus, which 250 
mirrors the histologic findings from these segments. However, we have recently shown that 251 
the score that takes into account the findings in both proximal and distal esophagus explained 252 
95% of variation (coefficient of determination) in endoscopist global assessment when 253 
compared to 90% of that captured by the score simply taking into account the most severe 254 
grade of all the features in the esophagus overall.[31] Therefore, it appears that the gain in 255 
separately scoring endoscopic features in proximal and distal esophagus is relatively small. 256 
Further studies are needed to examine the extent to which different EREFS-based scores 257 
explain variation in biologic disease severity assessed by means other than endoscopy. 258 
Unifying scoring recommendations may also aid in deriving EREFS-based remission and 259 
response definitions. Ideally, these outcome definitions should be derived from data-driven 260 
approaches rather than “expert opinion” alone. For example, anchor-based methods used for 261 
developing patient-reported outcome measure-based response definitions may be applied to 262 
establish meaningful within-patient change in EREFS based on expert endoscopists’ 263 
impression of change.[32] In summary, given that EREFS continues to undergo further 264 
refinement, it is likely that a certain degree of heterogeneity in endoscopic outcome 265 
assessment will persist at least in the near future. Nevertheless, EREFS in its current state will 266 
be recommended as part of COS for use in observational studies, and agreement on a unified 267 
 
 
scoring algorithm of EoE-associated endoscopic findings will undoubtedly lead to less 268 
heterogeneity in the outcome assessment in adults with EoE. These efforts will in turn facilitate 269 
the derivations of EREFS-based remission and response definitions. 270 
     In most observational studies examined in this review, the symptoms were assessed using 271 
non-validated tools; in the few remaining studies, PRO instruments not specifically validated 272 
for adult EoE patients (such as the Mayo Dysphagia Questionnaire and Watson Dysphagia 273 
Scale) were used. For example, although dysphagia improvement following dilation has been 274 
reported in multiple studies, patient-reported improvement in dysphagia characteristics 275 
following dilation requires evaluation using newly developed validated measures over a 276 
defined time period.[33] Although one could argue that the uptake of the validated tools for use 277 
in observational studies has been slow, it is also worth noting that the first study on validation 278 
of a PRO instrument was only published in 2013, and this PRO was copyrighted for use in a 279 
single RCT for the purpose of regulatory approval.[5] Despite existing issues with current 280 
symptom-based PRO tools, as no tool currently covers the entire spectrum of language used 281 
by patients to describe dysphagia, the assessment of patient-reported symptom- and quality 282 
of life-based outcomes in the context of observational studies should be carried out using 283 
validated instruments. Whilst tools with daily recall (such as Dysphagia Symptom 284 
Questionnaire/Dysphagia Symptom Diary) are most frequently used in RCTs aimed at drug 285 
approval, the use of a tool with a longer recall period (such as symptom-based eosinophilic 286 
esophagitis activity index, EEsAI, 7-day recall period) may be better logistically suited for adult 287 
EoE patients enrolled into observational studies or for non-registration trials.[4,5,18] As 288 
electronic data capture platforms continue to improve and creating secure medical mobile apps 289 
become less expensive, we postulate that daily electronic diaries will eventually transition from 290 
the realm of RCTs to being widely available in observational studies. Deriving response and 291 
remission definitions for daily and weekly symptom-based PRO tools remains a priority. For 292 
example, EEsAI PRO-based remission definition (score of ≤ 20 points) has been derived based 293 
on defining histologic and endoscopic remission in an observational study and successfully 294 
used in trials.[34,30] No remission definitions currently exist for other PRO tools. Although the 295 
 
 
US FDA has emphasized the use of anchor-based methods for deriving response definitions, 296 
these are yet to be published for any of the validated PRO instruments used in adults with EoE. 297 
Field-wide consensus on the use of the PRO tools in observational studies will undoubtedly 298 
reduce heterogeneity in outcome assessment in adults with EoE, and, hence, is urgently 299 
needed. 300 
     This review highlights several challenges that need to be overcome for standardization of 301 
outcome assessment. In this systematic review, we found many histologic remission definitions 302 
were used in observational studies of adults with EoE. The uptake of the EREFS has been the 303 
quickest, whilst uptake of the validated symptom-based PRO measures and EoEHSS has 304 
been slower to come. Although we evaluated the use of other more advanced molecular and 305 
genetic endpoints, these remain largely experimental. Measuring intraluminal distensibility 306 
using the Endoluminal Functional Lumen Imaging Probe shows a great promise although 307 
adoption in routine clinical practice remains limited. While the present study has strengths such 308 
as rigorous methodology and a comprehensive literature search, there are some limitations. 309 
These include the possibility that some pertinent studies may have been missed, as well as a 310 
lack of formal meta-analysis. We believe the search strategy minimized the chanced of missed 311 
data, and we do not feel that the data extracted were appropriate for pooled analysis 312 
techniques given the heterogeneity of the studies included and data assessed. 313 
     Given that many instruments for EoE outcome assessment in adults with EoE have been 314 
developed relatively recently, further refinement tools and use of data- and patient-driven 315 
approaches to define the response and remission thresholds are merited for improving 316 
outcome assessment in this condition. Further studies for informing the choice of outcomes 317 
assessed in various observational studies and clinical trials of adults with EoE are urgently 318 
needed. Although outcomes based on many of the state-of-the-art instruments are being used 319 
in trials designed to obtain regulatory approval for anti-inflammatory therapies for EoE, 320 
adapting these outcomes for purposes of observational studies may not always be feasible. 321 
For example, whilst the use of blinded central reading to reduce observation bias for 322 
endoscopy and histology in trials is being examined, this strategy is unlikely to be implemented 323 
 
 
in most observational studies. Despite these many challenges, standardization of outcome 324 
reporting is needed to facilitate validity of evidence synthesis and comparisons of interventions 325 
in meta-analyses in therapeutic trials in adults with EoE. This emphasizes the need for a 326 
community-wide exercise to seek agreement on COS to be reported in all observational studies 327 
and trials in adult EoE patients.  328 
 
 
Table 1. Characteristics of included studies describing outcome of treatment in adult patients 329 
with eosinophilic esophagitis. 330 
 331 
Characteristic Studies (n=69) Proportion of studies (%) 
Publication period 
2003 - 2006 
2007 - 2010 
2011 - 2014 
2015 - 2018 












































≤ 30 patients 
31 – 60 patients 
61 – 100 patients 





























a Number of studies, into which higher than indicated overall patient number was enrolled; 332 
however, these studies were categorized into a given category based on number of patients 333 
that underwent intervention of interest. 334 
 
 
Table 2. Histologic, endoscopic, symptom-based, and quality of life outcomes as well as biomarkers used in adult EoE patients treated with 335 


































(n = 21) 
 
Incl: ≥  20 
eos/hpf 
Fluticasone, 
0.22mg puffs 2x/d 
for 6 weeks 
 
Exact FU time 
 
Eos, BZH ≥  20 NR NR Dysphagia frequency and foods causing 
dysphagia (questionnaire not further 
described), duration of relief (subjective), 
and food impactions (symptoms assessed 6 














2x/d (5/6 patients) 




weaned over  
24 weeks)  
 




>24 Normal (not 
otherwise 
defined) 












Fluticasone n= 5/8) 
 







25 - ≥ 80  F, R Dysphagia, food impaction 












































Incl: ≥ 15 
eos/hpf 
Fluticasone, 
0.25mg 4x/d (2x2), 
4 weeks 
 














3.8 in distal 
esophagus 
WE, R, F, S, 
EE, narrowing 
(A/P)  
Based on DeMeester scores39,40 for 
heartburn, regurgitation, and dysphagia; 
chest pain, vomiting, abdominal pain and 
history of impaction. 
 
Symptom score for dysphagia, chest pain, 
heartburn, regurgitation, vomiting, and 
abdominal pain (each scored 0 to 3, total of 
18). 
 
(For dysphagia specifically, score of 
0=none; score of 1=occasional transient 
sensation of food sticking, score of 
2=episode of dysphagia requiring liquids to 
clear, score of 3= progressive dysphagia for 
solids requiring medical attention, need for 
dilation and bolus obstruction requiring 
hospital admission). 
 











































2x/d for  
12 weeks 
 











>24 0 WE, R, E, F, S, 
narrowing (A/P)  
Dysphagia, food impaction, epigastric 
oppression, heartburn, retrosternal pain, 
non-specific dyspeptic-type manifestations 
(A/P) 
 
Improvement in number of choking 
episodes, volume of liquid needed to drink 
with meals, time needed to eat lunch or 
dinner (minutes), capacity to swallow foods 
of different consistencies (each scored from 
















4puffs/d for 6 
weeks 
 
Mean FU: 3.3 years 
NR >20 NR No EGD 
performed 
Dysphagia (difficulty swallowing) frequency, 
food causing dysphagia, symptom 
recurrence, and food impactions (food 
sticking) 
 
Part of the questionnaire comes from Mayo 







































(n = 54) 
 
Incl: > 20 
eos/hpf 
Fluticasone 0.25mg 
4puffs/d (2x2) for 6 
weeks 
 




>20 NR NR Subjective symptom improvement (A/P) 
 
PRO: no 










Incl: ≥ 15 
eos/hpf 
Fluticasone 0.44mg 










partial if ≤ 15 
eos/hpf and 







WE, R, F (A/P)  Dysphagia frequency scale[46], reflux 
disease scale (heartburn, regurgitation, 
dyspepsia)[47] 
 
Improvement in dysphagia (8-point) scale 
(scoring from 0 to 7; score of 0=no 
dysphagia; 1=solid food dysphagia once in 
3–12 months; 2=solid food dysphagia once 
in 1–3 months; 3=solid food dysphagia once 
every 2–4 weeks; 4=solid food dysphagia 
once every 1–2 weeks;5=solid food 
dysphagia once every 1–7 days; 6=solid 
food dysphagia with every meal; 
7=dysphagia to solid and liquid food) 











































furoate 0.2mg 4x/d 
for 8 weeks 
 
Exact FU time 
 
 
Eos ≥ 20  NR NR Dysphagia frequency, quality of life 
 
Watson Dysphagia Score[49] ranging from 
0 to 45 (the presence of dysphagia for each 
liquid/solid substance scored on a 3-point 
Likert scale - 1=always, 0.5=sometimes, 
and 0=never)  
BL: 21.2 and EOT: 8.9 
 
Treatment of Cancer Quality of Life 
Questionnaire-Oesophageal Module 18 
(EORTC-QLQOES18)[50], scored from 0 to 
100, where a high score represents a high 
level of symptoms/problems. Consists of 4 
scales: the dysphagia, eating, reflux, and 
local pain each scored on 4-point Likert 
scale (not at all, sometimes, most of the 
time, and always) 
 













0.4mg/d for  
12 months 
 
Exact FU time 
 
 













EP upper:  
0.7, EP 
lower: 1.6;  
LP upper: 
0.4, LP 
lower: 2.7  
























































for 6 weeks 
 










46.7 NR, 57% in 
histologic 
remission 




Dysphagia severity using MDQ 30-day 
version[39] 
 
Change in subjective patient-reported 







12 Lee 2012[54] 
Case-control 
Prospective 






2x/d for 1wk 
followed by 3mg/d 
for 5wks, or 
fluticasone 0.88mg 
2x/d for  
6 weeks 
 














Dysphagia frequency and severity, food 
avoidance, foods causing dysphagia, 
impaction, heartburn, and acid regurgitation 
evaluated using MDQ 30-day version[39] 















































2x/d for  
6 weeks 
 











Median: 23  NA Based on DeMeester scores [38,39,40] for 
heartburn, regurgitation, and dysphagia; 
chest pain, vomiting, abdominal pain and 
history of impaction. 
 
Symptom score for dysphagia, chest pain, 
heartburn, regurgitation, vomiting, and 
abdominal pain (each scored 0 to 3, total of 
18). 
 
(For dysphagia specifically, score of 
0=none; score of 1=occasional transient 
sensation of food sticking, score of 
2=episode of dysphagia requiring liquids to 
clear, score of 3= progressive dysphagia for 
solids requiring medical attention, need for 
dilation and bolus obstruction requiring 
hospital admission). 
 





nitric oxide in 
non-asthma 











































2x/d for  
8 weeks 
 

















Dysphagia frequency and severity, food 
avoidance, foods causing dysphagia, 
impaction 
 
MDQ 2-week version[39] 
For study group treated with steroids: BL: 17 







































0.88mg/2x for  
8 weeks 
 




















































2x/d for  
12 weeks 
 





68.1 30.1 WE, R, F, S 
(A/P) 
Severity of dysphagia, heartburn, 
retrosternal pain, regurgitation and globus 
sensation assessed using Visual Analog 
Scale (VAS) each ranging from 0 to 10, 0= 
free of symptom, 10= unbearable 
symptom, total of 50) 
 




























NR NR EREFS Occurrence of food bolus impactions 














2x/d for  
8 weeks 
 









Subjective improvement in dysphagia and 














































2x/d or fluticasone 
0.88mg 2x/d for 
8 weeks 
 
Exact FU time 




























































2x/d for  
8 weeks 
 
Exact FU time 












BL: 4 and EOT: 
3 
Frequency and severity of dysphagia  
assessed using 6-point Likert scale, where 0 
represents “no dysphagia” and 5 
“daily/severe” dysphagia in analogy to reflux 
disease questionnaire[64] 
 
BL: 4 and EOT: 0 
 


















































































and FU: 23 months 
NA NA NA NA Dysphagia frequency, quality of life 
 
Watson Dysphagia Scale[49], EORTC-





Assessment at month 2 (after 2 months 
treatment with mometasone) and at least 12 












































Exact FU time 
Eos 
 








(0), mild (1), 
moderate (2) or 
severe (3) for a 
















Frequency and severity of dysphagia 
 
Straumann Dysphagia Index (SDI)[67] 













































2x/d or fluticasone 
0.44mg 2x/d for 
8 weeks 
 











WE, R, E, F, S 
(A/P) 


















2x/d or fluticasone 
0.88mg 2x/d for 
8 weeks 
 






















WE, R, E, F, S, 
crêpe-paper, 
narrowing (A/P) 



































26 Eluri 2017[70] 
Cohort 
Retrospective 
(n = 33/55 
treated and 









1.0mg 2x/d or 
fluticasone (10% of 
patients) or 0.44-
0.88mg 2x/d for 8 
weeks 
 





















WE, R, E, F, S 
crêpe-paper 
(A/P) 
Dysphagia, impaction, heartburn, and 
abdominal pain (A/P) 
 
























NR NR E, F, R, S, 
narrowing, 
crêpe-paper 
Dysphagia, food impaction, chest pain, 
heartburn, regurgitation, dyspeptic 
symptoms 











































2x/d or fluticasone 
0.88mg 2x/d for 
8 weeks 
 








Median: 2 WE, R, E, F, S, 
crêpe-paper 
(A/P) 
Dysphagia severity in the past 30 days (A/P) 
 
10-cm VAS (anchored at 0 with ‘no trouble 
swallowing’ and at 10 with ‘unable to even 
swallow saliva’), 10-point Likert scale 
(anchored at 0 with ‘not at all severe’ and at 
10 with ‘very severe’), and MDQ 30days[39] 
 
VAS: BL: 3.6 and EOT: 1.4 (p<0.001) 
Likert scale: BL: 6 and EOT: 2 (p<0.001) 















2x/d (induction for 
2-4 weeks), 



























































30 Kia 2018[74] 
Cohort 
Retrospective 





dose 0.5 mg 2x/d 
 
FU time: min. of 4 











furrows 0-2, for 
a total score of 












BL: 3.9 and 
EOT: 3.2 
Presence, frequency and duration of 
dysphagia and heartburn, chest pain 
EoEQ: EoE Questionnaire where five 
questions were asked, with each answer 
scored using a number ranging from 0 to 10 
depending on the number of answer choices. 
Responses from each question were then 
added with a maximum possible score of 24  















2x/d (induction for 
2-4 weeks), 
followed by  
0.25mg 2x/d 
(maintenance)  
















(WE, F, E), mild 
rings may be 
present  
Proportion of patients reaching clinical 
remission, defined as absence of any EoE-
attributed symptoms (dysphagia, 
retrosternal pain, heartburn) 
 












































1x/d for 8-12 
weeks, then 
reduction of dosage 
according to 
discretion of 
provider. Mean final 
compounded 
budesonide dosage 
of 2.2mg/d.  









Median: 15 WE,R,E,F,S Dysphagia, heartburn, chest pain, vomiting, 
global improvement (A/P)  
 

















Exact FU time 
Eos 123.7 34.6 WE, E, R, F, S, 
crêpe paper, 
narrowing (A/P, 
scored 0 to 5) 
Dysphagia severity in the past 30 days by 
VAS (A/P). 10-cm VAS (anchored at 0 with 
‘no trouble swallowing’ and at 10 with 
‘unable to even swallow saliva’)[72] 
 






































(n = 83 of 








dose of 2.107 mg 
1x/d or fluticasone 
mean dose of 1.707 
mg 1x/d for 8 
weeks 
 







128.1 35.1 EREFS Dyspepsia, heartburn 
 
SODA[78,79](severity of dyspepsia 
assessment): measures pain intensity, 
nonpain symptoms, and satisfaction with 
dyspepsia-related health. Scores range from 
11 to 105, with higher scores indicating more 
severe symptoms.  
 
QoL: GERD-HRQL[80,81] 
(gastroesophageal reflux disease health-
related quality of life). The heartburn-specific 
items were scored from 0 to 30, with ‘0’ 
indicating no heartburn symptoms and ‘30’ 
indicating the worst heartburn symptoms.  
 
Cases with histologic remission:  
GERD-HRQL: BL: 4.3 and EOT: 2.6 
SODA: BL: 39.9 and EOT: 35.5 
 
Cases without histologic remission: 
GERD-HRQL: BL: 5.2 and EOT: 3.1 










































Budesonide (n = 
22) or fluticasone (n 
= 60) <2.5mg/day 
 

















Bolus impaction (A/P) 
 
Physician’s global assessment (scoring NR) 
PRO: no 
NA 
Abbreviations: A/P, absence/presence; BL, baseline; BZH, basal zone hyperplasia; E, edema; EA, eosinophilic microabscesses; EE, erosive 338 
esophagitis; EORTC-QLQOES18, Treatment of Cancer Quality of Life Questionnaire-Oesophageal Module 18; Eos, eosinophils; EOT, end of treatment; 339 
EP, epithelium; F, furrows; FU, follow-up; hpf, high power field; LP, lamina propria; MDQ, Mayo Dysphagia Questionnaire; NA, not assessed; NR, not 340 
reported; NS, not significant; PRO, patient-reported outcome; R, rings; S, strictures; SDI, Straumann Dysphagia Index; VAS, visual analogue scale; 341 
WE, white exudates. 342 
a Majority of patients utilized STC. As such, the study was categorized as that related to use of STC to prevent double extraction, even though some 343 
patients might have been treated with other therapies.  344 
 
 
Table 3. Histologic, endoscopic, symptom-based, and quality of life outcomes as well as biomarkers used in adult EoE patients undergoing treatment 345 































































biopsies: the b 





































































complete ≤ 5 
eos/hpf; near 
complete ≤ 10 
eos/hpf; partial - > 















NR Frequency, intensity and duration of 
dysphagia episodes, lifestyle 
modifications related to dysphagia 
evaluated using non-validated instrument; 
range 2- 18, higher scores reflect greater 
dysphagia intensity[85] 
 
Score: BL: median 12 and EOT: median 
3.5 
 








(n = 67) 
 












count 0-5 eos/hpf, 
partial: 6-14 














NR Frequency and severity of the dysphagia, 
heartburn and regurgitation as assessed 
by instrument for achalasia by Zaninotto 
et al.[87] 
 
Score in responders: BL approx. 7.5 and 












































(n = 30) 
 








Eos 39.6 1.9 WE, R, E, F, S 
(A/P) 
Severity of dysphagia, chest pain when 
swallowing, globus sensation, 
regurgitation, heartburn, epigastric pain, 
impaction 
 
Visual Analogue Scale (ELSA-VAS EoE 
index, severity of each symptom scored 0 
– 10 for a total score ranging from 0 to 70) 
Score: BL 28.10 and EOT: NR 
 
PRO: yes 











(n = 18) 
 













as ≤5 eos/hpf, 
nearly complete 
as 6-10 eos/hpf, 
partial as ≥ 
10eos/hpf but 
final eos < half 
pretreatment eos 
count) 
54 10 WE, R, F, S 
(A/P) 
Dysphagia frequency and severity, food 
avoidance, heartburn, and acid 
regurgitation evaluated using 





























































defined as < 15 




















Frequency, intensity and duration of 
dysphagia episodes, lifestyle 
modifications related to dysphagia 
evaluated using non-validated instrument; 
range 2- 18, higher scores reflect greater 
dysphagia intensity[86] 
 
Remission defined as a decrease of more 
than 50% of baseline score after therapy 
Food impaction, heartburn (A/P) 
 
BL: 9.12 and EOT: 4.3 
 
PRO: yes  
NA 
7 Wolf 2014[91] 
Cohort 
Retrospective 
(n = 31) 
 













complete < 15 
eos/hpf and ≥  
50% reduction in 
peak eosinophil 
count 




Subjective symptom improvement (A/P) 
 












































(n = 43)  
 














14 eos/hpf, and 
failure ≥ 15 
eos/hpf 
Targeted
























WE, R, E, F, S 
(A/P)  
Severity of dysphagia, chest pain, globus 
sensation, regurgitation, heartburn, 
epigastric pain, impaction 
 
Visual Analogue Scale (ELSA-VAS EoE 
index, severity of each symptom scored 0 
– 10 for a total score ranging from 0 to 70) 
 
Targeted: BL: 27.1 and EOT: 5.31  










(n = 10) 
 
Incl: ≥ 15 
eos/hpf 
Empiric 





Eos, mast cells 56.8 3 NA Frequency and severity of the dysphagia, 
heartburn and regurgitation as assessed 
by instrument for achalasia by Zaninotto 
et al.[88] 
 
Score in responders: BL approx. 6 and 





































(n = 15) 
 


















EREFS Dysphagia assessed by non-specified 
score 
 
BL: 9.5 and EOT: 7 
 














































(n = 56/82 
treated) 
 















(n = 52) 
 
















60.3 44.8 EREFS 
BL: 4.1 and 
EOT: 2.7 (range 
0-9) 
Dysphagia, heartburn, chest pain, 
abdominal pain, patient-reported 
subjective improvement (A/P) 
 
No score used 
 









































(n = 17) 
 











complete if ≤15 
eos/hpf, partial if ≥ 
15 eos/hpf but 
with a decrease of 
more than 50% of 
pre-diet peak eos 
count 
40 9 EREFS 
including crêpe 
paper 
BL: 7 and EOT: 
3 
5‐point Likert scale (0 represents no 
symptoms in the past week and 5 
represents daily symptoms) for frequency 
of dysphagia, and 5‐point Likert scale (the 
where 0 represents no complains and 5 
represents severe complains) for severity 
of dysphagia. Total score ranged from 0 
to 10. Analogous to SDI. 
BL: 6 and EOT: 0 
 
Reflux disease questionnaire[64] 
 



















































































BL: average 4.3 
(range: 3-5)  
EOT: NR  
Dysphagia frequency and severity, food 
avoidance, heartburn, and acid 
regurgitation evaluated using Mayo 
Dysphagia Questionnaire (MDQ) 30-day 
version[43] 
Clinical response was assessed using the 
MDQ-30. Partial response was defined as 
continued symptoms, but with a frequency 
< once per week. Symptom remission was 
defined as an answer of “no” to the 
question of “Have you had trouble 
swallowing unrelated to a sore throat or 


































































(n = 17) 
 






















































































defined as <15 
eos/hpf 
38.5 5.2 EREFS Dysphagia, odynophagia, and food bolus 
impaction events graded as absent, mild, 
moderate or severe by treating physician, 
subjective symptom improvement (A/P) 
 





Abbreviations: A/P, absence/presence; BL, baseline; BZH, basal zone hyperplasia; E, edema; EA, eosinophilic microabscesses; EE, erosive 349 
esophagitis; EORTC-QLQOES18, Treatment of Cancer Quality of Life Questionnaire-Oesophageal Module 18; Eos, eosinophils; EOT, end of treatment; 350 
EP, epithelium; F, furrows; FU, follow-up; hpf, high power field; LP, lamina propria; MDQ, Mayo Dysphagia Questionnaire; NA, not assessed; NR, not 351 
reported; NS, not significant; PRO, patient-reported outcome; R, rings; S, strictures; SDI, Straumann Dysphagia Index; VAS, visual analogue scale; 352 




























































FU time: NR 









NR NR Chest pain, 
mucosal tear 
Dysphagia, chest pain, 
heartburn (A/P)  
 
Self-reported 
improvement by patients 



















FU time: 2 -- 10 
years 




NR NR Mucosal tear, 
perforation, 
chest pain 
Dysphagia, chest pain, 
nausea, vomiting, weight 
loss, diarrhea 
 
No score used 
 
PRO: no 
PPI (n = 2)  
Prednisone (n 




























































FU time: not 
applicable 







































































































FU time: 22 
months 
BL: 120 in 
proximal and 
165 in distal 
esophagus 
FU: 120 in 
proximal and 
165 in distal 
esophagus 
WE, R, F (A/P) 
 
Indication for 
dilation: severity of 
dysphagia and 
narrowing/stricture(s) 
NR 17 Chest pain Frequency of dysphagia 
assessed using non-




4=daily, and 5=every 
meal.  
 





























Swiss cohort  
BL: 121 
EOT: 104 
S: grade 1 = low-
grade stricture, 
diameter 11–13 mm, 
passage of the 
standard endoscope 
with elevated 
pressure; grade 2 = 
intermediate-grade 
stricture, diameter 
between 7 and 10 
mm, passage of 6 
mm endoscope 
possible, but 













Chest pain Dysphagia was 
evaluated using 
dysphagia score by Vakil 
et al108 (0 = able to eat a 
normal diet, 1 = 
dysphagia with some 
solid foods but able to 
eat other solid foods, 2 = 
able to eat semisolids 
only, unable to eat solids; 
3=able to swallow liquids 
only, 4 = complete 




















































gastroscope; grade 3 
= high-grade 
stricture, passage of 




(length ≤1cm) were 
differentiated from 
extensive strictures 




In Swiss cohort BL: 1.7 
and EOF: 0.9 
























Savary, TTB  
 
FU time: NR 
40 WE, R, S, crêpe-







refractory to medical 
treatment, iron 
deficiency anemia 






























































FU time: 5.2 
months 























9 Ally 2013[111] 
Case series 
Retrospective 
(n = 54/196 










FU time: NR 
NA WE, R, F, S, EE, 






NR ≥ 15 Chest pain, 
mucosal tear 














Maloney, TTB  
 
FU time: 13.6 
years 















































































FU time: 5 
years 






























































































stricture (A/P) and 
F (A/P), narrow 





Score at BL: 7.5 for 
proximal and 7.5 for 
distal esophagus 
NR NR Chest pain Dysphagia scores were 
classified on a 0–9 ordinal 
scale, with frequency of 
dysphagia assessed on a 
scale of 0–5 (0=never, 
1=less than 1day/week, 
2=1day/week, 3 = 2–3 
days/week, 4 = 4–6 
days/week, 5 = every day) 
and severity of dysphagia 
assessed on a scale of 0–
4 (0 = able to eat normal 
diet/no dysphagia, 1 = 
able to swallow some 
solid foods, 2 = able to 
swallow only semi-solid 
foods, 3 = able to swallow 








0.44 mg 2x/d 
and 
dexlansoprazol




























































FU time: 15 
months 















based on patient global 
report (A/P) 
 































in presence of 
narrowing/strict, 
ring(s) 

































































FU time:  
8/30: mean 



















No score used 
 
PRO: no 



























































































































stricture (A/P) and 
F (A/P), narrow 
calibre (A/P) 












Abbreviations: NR, not reported; NA, not assessed; FU, follow-up; hpf, high power field; Eos, eosinophilia; F, furrows; WE, white exudates; E, edema; 357 
R, rings; S, strictures; EE, erosive esophagitis; BL, baseline; EOT, end of treatment; A/P, absence/presence; PPI, proton-pump inhibitors; PRO, patient-358 
reported outcome; TTB, through-the-scope balloon. 359 
a Majority of patients were managed with dilation. As such, the study was categorized as that describing dilation to prevent double extraction, even 360 
though some patients might have been treated with other therapies. 361 
 
 
Table 5. Summary of EoE-related outcomes used in observational studies of swallowed topical corticosteroids and diet therapy. 362 
  Histology  Endoscopy Symptoms  Biomarkers/ 
Immunological 
Dissection  





Concepts described PRO 
(Y/N) 
 
STC studies        
Arora 2003 •  BZH  Dysphagia (language not specified) frequency, FCD, 
impactions 
  
Lucendo 2005 •  BZH, papillary 
elongation 
R,S Subjective symptom improvement  • 
Kumar 2005  •   F, R Dysphagia (language not specified) and impaction  • 
Remedios 2006 •   WE,R,F,S, 
narrowing 
Dysphagia (food sticking, SDI (liquid to clear), need to 
consult physician, or undergo dilation, or impaction 
requiring hospital admission) based on deMeester 
symptom score, chest pain, impaction 
*(scored) 
  





Dysphagia (choking, number of episodes), impactions, 
FCD, SAI/SDI (times required to eat a meal and volume 
of liquid), chest pain 
*(scored) 
•  
Helou 2008     Dysphagia (trouble swallowing) frequency, FCD, 
impactions, based on MDQ *(scored) 
•  
Enns 2010 •    Subjective improvement   
Peterson 2010 • complete ≤5 eos/hpf,  
partial ≤15 eos/hpf  
 WE,R,F Dysphagia (solid food dysphagia) frequency based on 
dysphagia frequency scale *(scored) 
•  
Bergquist 2011 •    Dysphagia (swallowing problem) frequency, FCD based 
on Watson Dysphagia Score 
Dysphagia (trouble eating, chocking when swallowing) 
severity, severity of pain when eating, severity of chest 
pain, based on EORTC QLQ-OES18 *(scored) 
•  
Lucendo 2011 •  LPF WE,R,F,S, 
crêpe-paper 
Subjective symptom improvement, impactions  • 
 
 
Francis 2012 • <5 eos/hpf  R,F Dysphagia (trouble swallowing) severity based on MDQ 
*(scored) 
•  
Lee 2012     Dysphagia (frequency and severity of trouble 
swallowing), SAI (food avoidance), FCD, impaction (food 
sticking), based on MDQ *(scored) 
•  
Leung 2012 • ≤7 eos/hpf   Dysphagia (food sticking), SDI (liquid to clear), need to 
consult physician, or undergo dilation, or impaction 
requiring hospital admission) based on deMeester 
symptom score, chest pain, impaction 
*(scored) 
• • 
Moawad 2013 • <7 eos/hpf  WE,R,F,S, 
crêpe-paper 
Dysphagia (frequency and severity of trouble 
swallowing), SAI (food avoidance), FCD, impaction (food 




•  EA WE,R,E,F,S, 
crêpe-paper 
Subjective symptom improvement   
Katzka 2014 •  spongiosis    • 
Schlag 2014 •  mast cells WE,R,F,S Severity of dysphagia (language not specified), 
retrosternal pain, and globus sensation assessed using 
0-10 VAS 
• • 





Impaction requiring endoscopic removal   
Iwakura 2015 •  basophils WE,R,F,S Subjective improvement of dysphagia (language not 
specified), impaction 
  
Dellon 2015 •   WE,R,E,F,S, 
crêpe-paper, 
narrowing 
  • 




(scoring 0 to 8) 
Frequency and severity of dysphagia (language not 
specified) assessed using 6-point Likert scale, where 0 
represents “no dysphagia” and 5 “daily/severe” dysphagia 
in analogy to reflux disease questionnaire *(scored) 
• • 
Larsson 2015     Dysphagia (swallowing problem) frequency, FCD based 
on Watson Dysphagia Score 
Dysphagia (trouble eating, chocking when swallowing) 
severity, severity of pain when eating, severity of chest 
pain, based on EORTC QLQ-OES18 *(scored) 
•  
Nennstiel 2016 •   WE,R,E,F,S, 
crêpe-paper, 
narrowing (each 
Frequency of dysphagia (trouble swallowing) and severity 




scored 0 to 3 for 
total of 21) 
impaction requiring endoscopic removal) based on 
Straumann Dysphagia Index 
*(scored) 
Albert 2016 • <15 eos/hpf  WE,R,E,F,S Subjective improvement   
Dellon 2016 •   WE,R,E,F,S, 
crêpe-paper, 
narrowing 
  • 
Eluri 2017 • <15 eos/hpf  WE,R,E,F,S, 
crêpe-paper 
Dysphagia (language not specified), impaction   
Vermeulen 2017 •   E, F, R, S, 
narrowing, 
crêpe-paper 
Dysphagia (difficulty of swallowing solid or liquid foods 
passing the oesophagus into the stomach), impaction 
(sensation of food bolus obstruction in the oesophagus), 
chest pain (pain located central or retrosternal on the 
chest following on consuming food), regurgitation (reflux 
of swallowed foods in the oropharyngeal cavity), 
heartburn (retrosternal or epigastric burning sensation in 
the chest or upper abdomen) 
  
Reed 2017 • <15 eos/hpf  WE,R,E,F,S, 
crêpe-paper 
Dysphagia (difficulty swallowing) severity based on 10-
cm VAS (0 with ‘no trouble swallowing’, 10 with ‘unable to 
even swallow saliva’), 10-point Likert scale (0 with ‘not at 
all severe’, 10 with ‘very severe’), and MDQ (frequency 
and severity of trouble swallowing, SAI (food avoidance), 
FCD, impactions (food sticking)) 
•  
Greuter 2017 • <5 eos/hpf LPF EREFS 
(scoring 0 to 9) 
Impaction   




furrows 0-2, for 
a total score of 
8) 
Dysphagia (frequency and severity of trouble swallowing), 
SAI (food avoidance and modification), FCD, heartburn, 
chest pain 
•  
Greuter 2018 • <15 eos/hpf  EREFS 
(scoring 0 to 8) 
*remission as 
absence of 
WE,F,E (mild R 
allowed) 
 





Reed 2018a • <15 eos/hpf  WE,R,E,F,S Dysphagia (language not specified), chest pain   
Reed 2018b •   WE,R,E,F,S, 
crêpe-paper, 
narrowing 
Dysphagia (difficulty swallowing) severity based on 10-
cm VAS (anchored at 0 with ‘no trouble swallowing’ and 
at 10 with ‘unable to even swallow saliva’) 
•  






   
Greuter 2020 • Remission defined as: <15 
eos/hpf; Deep remission 
defined as: 0–1 eos/hpf; 
Relapse defined as: ≥15 
eos/hpf 
 EREFS 
(scoring 0 to 8) 
Physician global assessment   
 363 
  Histology  Endoscopy Symptoms  Biomarkers/ 
Immunological 
Dissection 





Concepts described PRO 
(Y/N) 
 
Diet studies        
Hsu Blatman 
2011 
• <15 eos/hpf     • 
Gonsalves 2012 • complete ≤5 eos/hpf, 
near complete ≤10 eos/hpf,  
partial > 50% reduction in 
eos/hpf 
  Frequency, intensity and duration of dysphagia (attacks, 
retching, obstruction) episodes, lifestyle modifications 
related to dysphagia evaluated using Straumann 
instrument *(scored) 
•  
Lucendo 2013 • complete ≤5 eos/hpf,  
partial 6-14 eos/hpf,  
failure ≥ 15 eos/hpf 
  Frequency and severity of the dysphagia (language not 





•   WE,R,E,F,S Severity of dysphagia (difficulty swallowing), chest pain 
when swallowing, impaction based on VAS (0-10, ELSA-
VAS EoE index) *(scored) 
• • 
Peterson 2013 • complete ≤5 eos/hpf,  
near complete 6-10 eos/hpf,  
partial ≥ 10 eos/hpf AND final 
eos < 50% of pre-diet eos/hpf 
BZH, mast cells WE,R,F,S Dysphagia (difficulty swallowing) frequency and severity, 
FCD, SAI (food avoidance), impactions (food sticking) 






• <15 eos/hpf in both proximal 






Frequency, intensity and duration of dysphagia (attacks, 
retching, obstruction) episodes, lifestyle modifications 
related to dysphagia evaluated using Straumann 
instrument *(scored) 
•  
Wolf 2014 • <15 eos/hpf 





Subjective symptom improvement   
Rodriguez-
Sanchez 2014 
• complete <5 eos/hpf,  
partial 5-14 eos/hpf,  
failure ≥15 eos/hpf 
 WE,R,E,F,S Severity of dysphagia (difficulty swallowing), chest pain 
when swallowing, impaction based on VAS (0-10, ELSA-
VAS EoE index) *(scored) 
•  
Arias 2015 •  Mast cells  Frequency and severity of the dysphagia (language not 
specified) based on Zaninotto achalasia instrument 
*(scored) 
 • 
Van Rhijn 2015 • ≤10 eos/hpf EA, BZH, mast 
cells, spongiosis 
EREFS  
(scoring to 8) 
Dysphagia (language not specified) • • 
Philpott 2016 • <15 eos/hpf      
Reed 2017 • <15 eos/hpf  EREFS  
(scoring 0 to 9) 
Dysphagia (language not specified), chest pain   
Warners 2017a • complete ≤15 eos/hpf,  
partial ≥15 eos/hpf AND >50% 
reduction in pre-diet peak eos 
count 





Frequency and severity of dysphagia (trouble swallowing, 
both on 5-point Likert scale) analogous to SDI 
• • 
Eckmann 2017 • < 15 eos/hpf  EREFS  
(scoring 0 to 9) 
Dysphagia (frequency and severity of trouble 
swallowing), SAI (food avoidance), FCD, impaction (food 
sticking), based on MDQ *(scored) 
•  
Letner 2017 •   EREFS  
(scoring not 
specified) 
  • 




  • 




furrows 0-2, for 
a total score of 
8) 
Dysphagia (language not specified), odynophagia, and 
food bolus impaction events graded as absent, mild, 
moderate or severe by treating physician 





Table 6. Summary of EoE-related outcomes used in observational studies of dilation. 365 
Dilation studies Histology Endoscopy Symptoms Complications 
Croese 2003 • R, F, S, EE  Dysphagia (language not 
specified), chest pain 
• 
Kaplan 2003  R, stiff, ulcer, 
rent 
Dysphagia (language not 
specified), chest pain, nausea, 
vomiting, weight loss, diarrhea 
• 
Cohen 2007  WE, R, F, S  • 
Pasha 2007 • F, R, S, 
narrowing 
Dysphagia (language not 
specified), impaction, regurgitation 
• 
Bohm 2010 • WE, R, F PRO: Dysphagia frequency 
(language not specified) assessed 
using non-validated scale (from 
0=none, 1=monthly, 2=several 
times/month, 3=several 
times/week, 4=daily, and 5=every 
meal), food impaction 
• 
Schoepfer 2010 • S: 1 = low-grade 
stricture; 2 = 
intermediate-




≤1 cm and >1 
cm 
 
PRO: Dysphagia severity(language 
not specified) based on food 
consistencies (0 = able to eat a 
normal diet, 1 = dysphagia with 
some solid foods but able to eat 
other solid foods, 2 = able to eat 
semisolids only, unable to eat 
solids; 3=able to swallow liquids 
only, 4 = complete inability to eat) 
based on Vakil score 
 
Subjective dysphagia improvement 
and duration 
• 




Madanick 2011  WE, R, F, S, 
narrowing 
Subjective symptom improvement 
(language not specified) 
• 









Subjective dysphagia improvement 
(language not specified), 
dysphagia, food impaction 
• 
Ukleja 2014 • WE, R, E, F, S, 
EE, narrowing, 
Schatzki rings 
Dysphagia (language not 
specified), food impaction 
• 
Kavitt 2016 • EREFS (scoring 
0 to 9), crêpe-
paper, narrowing 
PRO: Dysphagia (trouble 
swallowing) frequency and severity 
Dysphagia scores were classified 
on a 0–9 ordinal scale, with 
frequency of dysphagia assessed 
on a scale of 0–5 (0=never, 1=less 
than 1day/week, 2=1day/week, 3 = 
2–3 days/week, 4 = 4–6 days/week, 
5 = every day) and severity of 
dysphagia assessed on a scale of 
0–4 (0 = able to eat normal diet/no 
dysphagia, 1 = able to swallow 
some solid foods, 2 = able to 
swallow only semi-solid foods, 3 = 
able to swallow liquids only, 4 = 
unable to swallow anything/total 
dysphagia). 
• 
Runge 2016 • WE, R, E, F, S, 
crêpe-paper, EE, 
narrowing 
Subjective symptom improvement • 




Lipka 2018  S  Not specified • 
Schupack 2020 • S, narrowing, 
Schatzki rings 
Dysphagia (language not 
specified), heartburn, regurgitation, 
food impaction 
 
Kim 2020 • EREFS  
(scoring 0 to 9), 
narrowing 
 • 
Abbreviations: F, furrows; WE, white exudates; E, edema; R, rings; S, strictures; EE, erosive esophagitis; A/P, absence/presence; PRO, patient-366 
reported outcome. 367 
 
 
Supplementary File 1. Search strategy 368 
MEDLINE (OVID) 369 
1     exp Esophagitis/  370 
2     esophag*.tw.  371 
3     oesophag*.tw.  372 
4     1 or 2 or 3  373 
5     exp Eosinophils/  374 
6     exp Eosinophilia/  375 
7     eosinophil*.tw.  376 
8     5 or 6 or 7  377 
9     4 and 8  378 
10     Epidemiologic Studies/  379 
11     exp Case-Control Studies/ 380 
12     exp Cohort Studies/ 381 
13     Cross-Sectional Studies/  382 
14     (epidemiologic adj (study or studies)).tw.  383 
15     case control.tw.  384 
16     (cohort adj (study or studies)).tw.  385 
17     cross sectional.tw.  386 
18     cohort analy*.tw.  387 
19     (follow up adj (study or studies)).tw.  388 
20     longitudinal.tw.  389 
21     retrospective*.tw.  390 
22     prospective*.tw.  391 
23     (observ$ adj3 (study or studies)).tw.  392 
24     adverse effect?.tw.  393 
25     10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23 or 24  394 
26     ((identify$ or develop$ or design$ or test$ or assess$ or evaluat$ or robust$ or optim$  395 
or effic$ or effect$ or sensitiv$ or simpl$ or specific$ or precis$) adj3 (search strat$ or  396 
search filter?)).tw.  397 
27     25 and 26  398 
28     exp animals/ not humans/  399 
29     25 not 28  400 
 
 
30     9 and 29  401 
31     swallowed.tw.  402 
32     exp Administration, Topical/  403 
33     exp Steroids/  404 
34     fluticasone.tw.  405 
35     mometasone.tw.  406 
36     exp Budesonide/  407 
37     corticosteroid*.tw.  408 
38     exp Glucocorticoids/  409 
39     31 or 32 or 33 or 34 or 35 or 36 or 37 or 38  410 
40     30 and 39  411 
41     exp Diet/  412 
42     diet.tw.  413 
43     dieta*.tw.  414 
44     diete*.tw.  415 
45     41 or 42 or 43 or 44  416 
46     30 and 45  417 
47     dilation*.tw.  418 
48     dilatation*.tw.  419 
49     47 or 48  420 
50     30 and 49  421 
51     40 or 46 or 50  422 
52     exp "review"/  423 
53     51 not 52  424 
  425 
 
 
Supplementary Figure 1. The flow diagram.  426 
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